Patents Assigned to Connaught Laboratories Limited
-
Patent number: 5439810Abstract: Protein expression levels from Bordetella strains, particularly Bordetella pertussis, are altered by genetic modification to a natural Bordetella strain whereby one or more of the natural genes, particularly including the TOX, FHA, CYA and PRN genes, is deleted from the genome of the natural strain and one or more of the natural genes or a genetic mutation thereof, particularly a genetically-detoxified TOX* gene, or a hybrid gene, is inserted into the genome of the natural strain to provide at least two copies of one or more of the natural genes or genetic mutation thereof or hybrid gene, singly or in tandem. The altered genotype Bordetella strain is useful in producing whole-cell or defined component vaccines against Bordetella, particularly whooping cough, which may be employed in combination with other vaccines.Type: GrantFiled: July 9, 1992Date of Patent: August 8, 1995Assignee: Connaught Laboratories LimitedInventors: Sheena Loosmore, Gavin Zealey, Reza Yacoob, Michel Klein
-
Patent number: 5439809Abstract: An immunogenic HIV retrovirus-like particle which is non-infectious and non-replicating and which is useful as a candidate vaccine component against HIV infection, is produced by genetic engineering. A DNA molecule comprising the HIV genome devoid of long terminal repeats is incorporated into an expression vector, which is introduced into mammalian cells for expression of the HIV retrovirus-like particle.Type: GrantFiled: June 15, 1992Date of Patent: August 8, 1995Assignee: Connaught Laboratories LimitedInventors: Joel Haynes, Michel H. Klein, Benjamin Rovinski, Shi X. Cao
-
Patent number: 5433945Abstract: A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this information, defined mutant holotoxins have been produced by site directed mutagenesis of the toxin gene. A number of these holotoxin analogues are detoxified, retain an immunodominant S1 epitope, are immunogenic and are protective in the standard pertussis vaccine potency test in mice.Type: GrantFiled: November 20, 1992Date of Patent: July 18, 1995Assignee: Connaught Laboratories LimitedInventors: Michel H. Klein, Heather A. Boux, Stephen A. Cockle, Sheena M. Loosmore, Gavin R. Zealey
-
Patent number: 5358868Abstract: A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this information, defined mutant holotoxins have been produced by site directed mutagenesis of the toxin gene. A number of these holotoxin analogues are detoxified, retain an immunodominant S1 epitope, are immunogenic and are protective in the standard pertussis vaccine potency test in mice.Type: GrantFiled: November 5, 1991Date of Patent: October 25, 1994Assignee: Connaught Laboratories LimitedInventors: Michel H. Klein, Heather A. Boux, Stephen A. Cockle, Sheena M. Loosmore, Gavin R. Zealey
-
Patent number: 5332583Abstract: A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this information, defined mutant holotoxins have been produced by site directed mutagenesis of the toxin gene. A number of these holotoxin analogues are detoxified, retain an immunodominant S1 epitope, are immunogenic and are protective in the standard pertussis vaccine potency test in mice.Type: GrantFiled: November 5, 1991Date of Patent: July 26, 1994Assignee: Connaught Laboratories LimitedInventors: Michel H. Klein, Heather A. Boux, Stephen A. Cockle, Sheena M. Loosmore, Gavin R. Zealey
-
Patent number: 5244657Abstract: A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this information, defined mutant holotoxins have been produced by site directed mutagenesis of the toxin gene. A number of these holotoxin analogs are detoxified, retain an immunodominant S1 epitope, are immunogenic and are protective in the standard pertussis vaccine potency test in mice.Type: GrantFiled: September 28, 1990Date of Patent: September 14, 1993Assignee: Connaught Laboratories LimitedInventors: Michel H. Klein, Heather A. Boux, Stephen A. Cockle, Sheena M. Loosmore, Gavin R. Zealey
-
Patent number: 5221618Abstract: A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this information, defined mutant holotoxins have been produced by site directed mutagenesis of the toxin gene. A number of these toxin analogues are detoxified, retain an immunodominant S1 epitope, are immunogenic and are protective in the standard pertussis vaccine potency test in mice.Type: GrantFiled: September 30, 1991Date of Patent: June 22, 1993Assignee: Connaught Laboratories LimitedInventors: Michel H. Klein, Heather A. Boux, Stephen A. Cockle, Sheena M. Loosmore, Gavin R. Zealey
-
Patent number: 5194254Abstract: A new method is described for eliciting IgG antibody response to proteins or synthetic peptides, particularly those that are weakly immunogenic, without the requirement for the use of adjuvants, thereby making it easier and safer to confer protection against pathogenic organisms. The antigen is coupled to a monoclonal antibody, specific for membrane determinants expressed on certain types of mammalian recipient cells, called antigen presenting cells. The monoclonal antibody acts as a "vector" or "delivery vehicle" for targeting foreign antigens onto such recipient cells. This targeting facilitates subsequent antigen recognition by helper T-cells, which are pivotal in helping the induction of antigen-specific IgG responses.Type: GrantFiled: October 13, 1989Date of Patent: March 16, 1993Assignee: Connaught Laboratories LimitedInventors: Brian H. Barber, George Carayannotis
-
Patent number: 5085862Abstract: A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this information, defined mutant holotoxins have been produced by site directed mutagenesis of the toxin gene. A number of these toxin analogues are detoxified, retain an immunodominant S1 epitope, are immunoganic and are protective in the standard pertussis vaccine potency test in mice.Type: GrantFiled: November 23, 1988Date of Patent: February 4, 1992Assignee: Connaught Laboratories LimitedInventors: Michel H. Klein, Heather A. Boux, Stephen A. Cockle, Sheena M. Loosmore, Gavin R. Zealey
-
Patent number: 5061619Abstract: A novel immunoassay techniques is provided which is useful in the detection and determination of antibodies to antigens. Antibodies of all classes to a given antigen or the specific subclass of immunoglobulin to a specified antigen can be detected. A conjugate of labelled antibody and specific antigen is used as the third reagent in a sandwich assay.Type: GrantFiled: August 22, 1990Date of Patent: October 29, 1991Assignee: Connaught Laboratories LimitedInventors: Strathearn Wilson, Robert J. Dwyer
-
Patent number: 4997915Abstract: Lymphocytosis promoting factor (LPF) and filamentous hemaglutinin (FHA) are isolated from the growth medium of the Bordatella pertussis organism and purified by selecting adsorbing the LPF and FHA on a selective adsorbing medium, such as filter aids or gel filtration media, at low ionic strength and subsequently removing the adsorbed LPF and FHA at using an aqueous medium of high ionic strength, either simultaneously or sequentially. Prior to desorbtion of the LPF and FHA, the adsorbing medium may be contacted with an aqueous solution of a non-ionic detergent, which enables the LPF and FHA subsequently desorbed to be substantially free from contamination by lipopolysaccharides (LPS). The LPF and FHA may be further purified on hydroxyapatite. The LPF and FHA may be detoxified separately or together by contacting with a cross-linking agent, such as glutaraldehyde or formaldehyde, in the presence of an anti-aggregation agent.Type: GrantFiled: April 6, 1989Date of Patent: March 5, 1991Assignee: Connaught Laboratories LimitedInventors: Larry U. L. Tan, Dirk Alkema, Gail Jackson, Po S. Wah
-
Patent number: 4956128Abstract: Perfectly spherical, smooth and uniform microcapsules, which may contain living cells, are produced having a diameter less than 700 .mu.m by employing an electrostatic droplet generator. A droplet is suspended from a pointed source, such as a needle, and is charged with high static voltage. A collecting vessel or ring device is charged with opposing polarity and attracts the droplet. When a voltage potential threshold is passed, the droplet moves from the source to the collecting vessel. The voltage pulse height, pulse frequency and length, and extrusion rate of the droplets are adjustable so that predetermined sizes of droplets may be repeatedly generated and collected.Type: GrantFiled: November 13, 1986Date of Patent: September 11, 1990Assignee: Connaught Laboratories LimitedInventors: Martin Hommel, Anthony M. Sun, Mattheus F. A. Goosen
-
Patent number: 4950480Abstract: A new method is described for eliciting IgG antibody response to proteins or synthetic peptides without the requirement for the use of adjuvants, thereby making it easier and safer to confer protection against pathogenic organisms. The antigen is coupled to a monoclonal antibody, specific for membrane determinants expressed on certain types of mammalian recipient cells, called antigen presenting cells. The monoclonal antibody acts as a "vector" or "delivery vehicle" for targeting foreign antigens onto such recipient cells. This targeting facilitates subsequent antigen recognition by helper T-cells, which are pivotal in helping the induction of antigen-specific IgG responses.Type: GrantFiled: May 5, 1987Date of Patent: August 21, 1990Assignee: Connaught Laboratories LimitedInventors: Brian H. Barber, George Carayannotis
-
Patent number: 4849508Abstract: Pasteurization of immunoglobulin solutions to inactivate viruses without significantly altering the IgG molecules or their physiological activities is obtained with minimal aggregation in the absence of any stabilizer by heating this solution to mildly-elevated temperatures at low ionic strength and mildly acid pH values.Type: GrantFiled: November 24, 1987Date of Patent: July 18, 1989Assignee: Connaught Laboratories LimitedInventors: Anthony A. Magnin, Po-Shing Wah, Paul Dennis
-
Patent number: 4806355Abstract: Living tissue or cells, for example, islets of Langerhans, are microencapsulated for implantation in the body for long term treatment of diabetes or other disease requiring organ transplantation. The microcapsules take the form of a biocompatible semi-permeable hydrogel membrane which permits the passage of materials and oxygen to the cells and metabolic products from the cells while retaining the cells encapsulated. The biocompatible semi-permeable membrane has an outer negatively-charged surface, which imparts to the microcapsules the ability to maintain long term effectiveness.Type: GrantFiled: June 8, 1987Date of Patent: February 21, 1989Assignee: Connaught Laboratories LimitedInventors: Mattheus F. A. Goosen, Geraldine M. O'Shea, Anthony M. F. Sun
-
Patent number: 4789550Abstract: Perfectly spherical, smooth and uniform microcapsules, which may contain living cells, are produced having a diameter less than 700 .mu.m, e.g. 150 to about 500 microns, by employing an electrostatic droplet generator. A droplet is suspended from a pointed source, such as a needle, and is charged with high static voltage. A collecting vessel or ring device is charged with opposing polarity and attracts the droplet When a voltage potential threshold is passed, the droplet moves from the source to the collecting vessel. The voltage pulse height, pulse frequency and length, and extrusion rate of the droplet are adjustable so that predetermined sizes of droplets may be repeatedly generated and collected.Type: GrantFiled: July 16, 1984Date of Patent: December 6, 1988Assignee: Connaught Laboratories LimitedInventors: Martin Hommel, Anthony Mein-Fang Sun, Mattheus F. A. Goosen
-
Patent number: 4689293Abstract: Living tissue or cells, for example, islets of Langerhans, are microencapsulated for implantation in the body for long term treatment of diabetes or other disease requiring organ transplantation. The microcapsules take the form of a biocompatible semi-permeable hydrogel membrane which permits the passage of materials and oxygen to the cells and metabolic products from the cells while retaining the cells encapsulated. The biocompatible semi-permeable membrane has an outer negatively-charged surface, which imparts to the microcapsules the ability to maintain long term effectiveness.Type: GrantFiled: December 4, 1984Date of Patent: August 25, 1987Assignee: Connaught Laboratories LimitedInventors: Mattheus F. A. Goosen, Geraldine M. O'Shea, Anthony M. F. Sun
-
Patent number: 4673566Abstract: Living tissue or cells, for example, islets of Langerhans, are microencapsulated for implantation in the body for long term treatment of diabetes or other disease requiring organ transplantation. The microcapsules take the form of a biocompatible semi-permeable hydrogel membrane based on polylysine which permits the passage of materials and oxygen to the cells and metabolic products from the cells while retaining the cells encapsulated. The biocompatible semi-permeable membrane has an outer negatively-charged surface, which, combined with a controlled thickness of polylysine of molecular weight from 10,000 to 30,000 daltons, imparts to the microcapsules the ability to maintain long term effectiveness.Type: GrantFiled: May 24, 1984Date of Patent: June 16, 1987Assignee: Connaught Laboratories LimitedInventors: Mattheus F. A. Goosen, Geraldine M. O'Shea, Anthony M. Sun
-
Patent number: 4650673Abstract: A composition and method for immunizing carnivores and other mammals, especially foxes, against rabies and other pathogenic diseases, by setting out and orally administering a dose of a vaccine, are described. The vaccine is enclosed in a bite-permeable sponge-like vector and the container is coated with a membrane containing an attractant, such as tallow. The method operates by penetration of a sponge resulting in distribution of relatively large volumes of vaccine to the oropharyngeal cavity of the mammals.Type: GrantFiled: September 9, 1985Date of Patent: March 17, 1987Assignee: Connaught Laboratories LimitedInventors: David Johnston, Kenneth F. Lawson
-
Patent number: 4492684Abstract: A slow release injectable insulin composition is provided which is able to control blood sugar levels over extended periods of time. The albumin is partially cross-linked using a concentration of glutaraldehyde which is less than 3.75% v/w of the albumin to form a matrix enclosing the insulin. The composition conveniently is provided in the form of microbeads.Type: GrantFiled: June 20, 1983Date of Patent: January 8, 1985Assignee: Connaught Laboratories LimitedInventors: Mattheus F. A. Goosen, Anthony M. F. Sun